Insight Molecular Diagnostics (IMDX) Stock Statistics & Valuation Metrics

Insight Molecular Diagnostics has a market cap or net worth of $206.98M. The enterprise value is $146.92M.

Insight Molecular Diagnostics has 32,290,170 shares outstanding. The number of shares has decreased by -2.65% in one year.

Insight Molecular Diagnostics’s return on equity (ROE) is 1.60 and return on invested capital (ROIC) is -197.43%.

The current PE Ratio of Insight Molecular Diagnostics is ―. Insight Molecular Diagnostics’s PEG ratio is 0.07.

In the last 12 months, Insight Molecular Diagnostics had revenue of 4.05M and earned -50.22M in profits. Earnings per share was -1.65.

In the last 12 months, operating cash flow was -23.96M and capital expenditures -3.49M, giving a free cash flow of -27.46M billion.

Insight Molecular Diagnostics pays an annual dividend of ―, resulting in a dividend yield of ―

Insight Molecular Diagnostics upcoming earnings date is Aug 6, 2026, After Close (Confirmed).

Insight Molecular Diagnostics as a current ratio of 1.27, with Debt / Equity ratio of -28.71%

In the past 12 months, Insight Molecular Diagnostics has paid 0.00 in taxes.

Insight Molecular Diagnostics EV to EBITDA ratio is -7.77, with an EV/FCF ratio of -8.69.

Insight Molecular Diagnostics has $28.20M in cash and marketable securities with $3.07M in debt, giving a net cash position of $25.13M billion.

Gross margin is 19.47%, with operating margin of -754.08%, and net profit margin of -1238.52%.

The average price target for Insight Molecular Diagnostics is $10.50, which is 11.43% higher than the current price. The consensus rating is Moderate Buy